Canadian Life Sciences NewsUncategorized

Lexston Announces a Memorandum Of Understanding to Collabborate on Psychedelics Research and Development with Alvarius Research Inc.

Lexston Announces a Memorandum Of Understanding to Collabborate on Psychedelics Research and Development with Alvarius Research Inc.


Lexston Life Sciences Corp.

Vancouver, British Columbia –
TheNewswire –
January 12, 2022.
Lexston Life Sciences Corp. (the

(OTC:LEXTF) is pleased to announce the
of a Memorandum of Understanding (the


) between its wholly owned subsidiary Egret Bioscience Ltd.
) and
Alvarius Research

”; a wholly owned subsidiary of
Lighthouse Genomics Inc
a leading research
and development company focused on ex situ conservation and genomic
resource development for the Colorado River toad (
Incilius alvarius

Under the terms of the MOU, Egret and Alvarius intend
elucidate the biosynthetic pathways leading
to the entourage of tryptamines (5-MeO-DMT, 5-MeO-tryptamine,
5-HO-N-methyltryptamine, Bufotenin and DMT) produced in the
parotoid glands secretions. Alvarius
recently commenced an ex situ conservation program with eight
individual toads from two independent captive populations and have
developed ethical means to harvest parotoid gland secretions. The
latter are in the process of
being chemically
characterized via tryptamine profiling using the Egret High Pressure
Liquid Chromatography (HPLC) assay and will be used to record
intra-individual variation in tryptamine profiles with the goal of
identifying individuals to set up future breeding populations.

Subsequent research will investigate genes uniquely
expressed in parotoid glands. A reference genome will be assembled
with the ultimate goal to
enhance ethical and
humane ex situ conservation programs and to develop genomic resources
to assist the conservation of the species in the wild. The teams will
also jointly develop an alternative to synthetic toad-free tryptamine
production using a cell-based culture pipeline to produce the
compounds of interest while retaining the natural entourage. Such
compounds have shown promise in the treatment of a variety of
indications including cluster headaches, and major depressive

“We are excited to move forward with this significant
project. The Colorado River toad parotoid glands may represent the
most efficient natural factories for tryptamines such as 5-Meo-DMT,
reaching concentrations as high as 45% total secretion mass. The
conservation status of this species in the wild has made it
challenging to work with, however we expect that our collaboration
with Alvarius will ensure that alternative means to produce natural
tryptamines will be in place to accommodate the anticipated demand for
this class of psychedelics,” stated Dr. Philippe Henry, Chief
Science Officer and Director of Lexston.

“This collaboration with Egret carries multiple
dimensions of beneficial impact,” stated Timothy Harvey, Director of
Alvarius Research. “The advent of full-spectrum biosynthetic toad
tryptamines will take pressure off toad populations as the supply of
therapeutic psychoactive compounds. There is currently no alternative
source of the full-spectrum gland secretions, which puts wild
populations under tremendous pressure as demand increases from a
growing number of therapeutic programs, which aim to improve human
psychological health. To provide a biosynthetic supply to these
important therapeutic programs, in addition to stimulating needed
research into the conservation status of wild populations, links our
business success to improved outcomes for the toad. It is a
regenerative business model based on respect for this unique and
remarkable species.”

Click Image To View Full Size

Mugshot of “Little Buddha” one of the 7 year old
Colorado river toads in the Alvarius’ terrarium at Salt Spring
Island BC.

For more information and to subscribe to the
Company’s mailing list, please visit

About Lexston Life Sciences

Lexston Life Sciences Corp. is a Canadian biotechnology
company providing cannabis testing and research services. Lexston is
also in the process of securing licensing under the exemptions
prescribed by section 56 of the Controlled Drugs and Substances Act
(Canada) to enable the expansion of its services into the psychedelic
industry with an initial focus on the detection and quantification of
psychedelic molecules in the lab and point of care. Lexston intends to
develop and validate methods for standardized
manufacturing of plant derived psychedelics in support of
burgeoning trials in the field of mental health and wellness.

On Behalf of the Board of Directors


Jagdip Bal Chief Executive Officer

Telephone: (604) 928-8913

Forward-Looking Statements

This news release contains forward-looking statements
and information within the meaning of applicable securities
legislation. Often, but not always, forward-looking statements and
information can be identified by the use of words such as “plans”,
“expects” or “does not expect”, “is expected”,
“estimates”, “intends”, “anticipates” or “does not
anticipate”, or “believes”, or variations of such words and
phrases or state that certain actions, events or results “may”,
“could”, “would”, “might” or “will” be taken, occur or
be achieved. Forward looking statements or information involve known
and unknown risks, uncertainties and other factors which may cause the
actual results, performance, or achievements of LEXT to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements or information
contained in this news release.

Risks, uncertainties, and other factors involved with
forward-looking information could cause actual events, results,
performance, prospects, and opportunities to differ materially from
those expressed or implied by such forward-looking information. The
Canadian Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this
news release.

Copyright (c) 2022 TheNewswire – All rights reserved.

Related Articles

Back to top button